Provided herein, inter alia, nucleic acids including coding sequences for human CD80, IL-15, IL-15R polypeptides, wherein the coding sequence for hCD80 is operably positioned upstream to the coding sequences for hIL-15 and hIL-15R. The disclosure also provides recombinant cells, cell cultures, pharmaceutical compositions, and whole-cell vaccines containing the recombinant cells disclosed herein. Also disclosed are methods useful for treating myeloma and leukemias, such as acute myelogenous leukemia (AML).

Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

A virus vector comprises a constitutive promoter, a nucleic acid sequence encoding a chimeric antigen receptor (CAR), an inducible promoter comprising N nuclear factor of activated T-cells (NFAT) binding motifs followed by the minimal human interleukin 2 (IL-2) promoter, and a nucleic acid sequence encoding a Helicobacter pylori neutrophil activating protein (HP-NAP) and/or an immunological equivalent fragment thereof. The virus vector may be provided in a T-cell useful in T-cell immunotherapy. The T-cells have improved effects in immunotherapy including treating, reducing and/or preventing cancer in a patient.

A virus vector comprises a constitutive promoter, a nucleic acid sequence encoding a chimeric antigen receptor (CAR), an inducible promoter comprising N nuclear factor of activated T-cells (NFAT) binding motifs followed by the minimal human interleukin 2 (IL-2) promoter, and a nucleic acid sequence encoding a Helicobacter pylori neutrophil activating protein (HP-NAP) and/or an immunological equivalent fragment thereof. The virus vector may be provided in a T-cell useful in T-cell immunotherapy. The T-cells have improved effects in immunotherapy including treating, reducing and/or preventing cancer in a patient.

The present invention provides a CAR-T cell constructed on the basis of a natural protein TSH. The present invention provides a chimeric antigen receptor constructed on the basis of a TSH subunit and TSH subunit tandem structure, a CAR-T cell, and a use thereof. The TSH-CAR-T cell of the present invention can kill TSHR-positive thyroid cancer cells in a targeted manner, and has no immunogenicity, so that the TSH-CAR-T cell has the prospect of being used in the treatment of thyroid cancer.